M. Hackel

发表

Global spread of carbapenem-resistant Acinetobacter baumannii.

P. Higgins, Cathrin Dammhayn, M. Hackel, 2010, The Journal of antimicrobial chemotherapy.

Increasing prevalence and dissemination of NDM-1 metallo-β-lactamase in India: data from the SMART study (2009).

R. Bonomo, A. Hujer, M. Hackel, 2011, The Journal of antimicrobial chemotherapy.

Global Incidence of Carbapenemase-Producing Escherichia coli ST131

G. Peirano, K. Kazmierczak, M. Hackel, 2014, Emerging infectious diseases.

Antimicrobial susceptibility and extended-spectrum beta-lactamase rates in aerobic gram-negative bacteria causing intra-abdominal infections in Vietnam: report from the Study for Monitoring Antimicrobial Resistance Trends (SMART 2009-2011).

M. Hackel, D. Hoban, T. Nga, 2014, Diagnostic microbiology and infectious disease.

A Review of Ten Years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011

I. Morrissey, M. Hackel, S. Hawser, 2013, Pharmaceuticals.

Antimicrobial susceptibility of Enterobacteriaceae, including molecular characterization of extended-spectrum beta-lactamase-producing species, in urinary tract isolates from hospitalized patients in North America and Europe: results from the SMART study 2009-2010.

L. Nicolle, M. Hackel, D. Hoban, 2012, Diagnostic microbiology and infectious disease.

Low frequency of ertapenem-resistant intra-abdominal isolates of Escherichia coli from Latin America: susceptibility, ESBL-occurrence, and molecular characterisation (SMART 2008–2009)

M. Hackel, F. Rossi, D. Hoban, 2012, Journal of chemotherapy.

Multiyear, Multinational Survey of the Incidence and Global Distribution of Metallo-β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa

K. Kazmierczak, M. Hackel, P. Bradford, 2015, Antimicrobial Agents and Chemotherapy.

Fluorocycline TP-271 Is Potent against Complicated Community-Acquired Bacterial Pneumonia Pathogens

T. Grossman, M. Hackel, A. Slee, 2017, mSphere.

In Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015

K. Kazmierczak, M. Hackel, P. Bradford, 2017, Antimicrobial Agents and Chemotherapy.

In Vitro Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies, 2014 to 2019

M. Hackel, J. Karlowsky, R. Echols, 2021, Antimicrobial agents and chemotherapy.

In Vitro Activity of Ceftibuten/VNRX-5236 against Urinary Tract Infection Isolates of Antimicrobial-Resistant Enterobacterales

M. Hackel, J. Karlowsky, D. Sahm, 2021, Antimicrobial agents and chemotherapy.

In Vitro Activity of Gepotidacin against Gram-Negative and Gram-Positive Anaerobes

M. Hackel, J. Karlowsky, D. Sahm, 2021, Antimicrobial agents and chemotherapy.

In Vitro Activity of WCK 5222 (Cefepime-Zidebactam) against Worldwide Collected Gram-Negative Bacilli Not Susceptible to Carbapenems

M. Hackel, J. Karlowsky, D. Sahm, 2020, Antimicrobial Agents and Chemotherapy.

Escherichia coli strains possessing a four amino acid YRIN insertion in PBP3 identified as part of the SIDERO-WT-2014 surveillance study

K. Kazmierczak, M. Hackel, D. Sahm, 2020, JAC-antimicrobial resistance.

Analysis of Potential β-Lactam Surrogates To Predict In Vitro Susceptibility and Resistance to Ceftaroline for Clinical Isolates of Enterobacteriaceae

M. Hackel, J. Karlowsky, D. Sahm, 2018, Journal of Clinical Microbiology.

In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016

M. Hackel, J. Karlowsky, R. Echols, 2017, Antimicrobial Agents and Chemotherapy.

Resistance among Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Latin American countries: SMART 2013–2015

M. Hackel, J. Karlowsky, D. Hoban, 2017, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

Determination of Disk Diffusion and MIC Quality Control Ranges for Nafithromycin (WCK 4873), a New Lactone-Ketolide

M. Hackel, J. Karlowsky, D. Dressel, 2017, Journal of Clinical Microbiology.

In Vitro Activity of Imipenem-Relebactam against Gram-Negative ESKAPE Pathogens Isolated by Clinical Laboratories in the United States in 2015 (Results from the SMART Global Surveillance Program)

K. Kazmierczak, M. Hackel, M. Motyl, 2017, Antimicrobial Agents and Chemotherapy.

In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study)

M. Hackel, J. Karlowsky, R. Echols, 2017, Antimicrobial Agents and Chemotherapy.

In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae

M. Hackel, J. Karlowsky, M. Dudley, 2017, Antimicrobial Agents and Chemotherapy.

Assessment of the In Vitro Activity of Ceftazidime-Avibactam against Multidrug-Resistant Klebsiella spp. Collected in the INFORM Global Surveillance Study, 2012 to 2014

K. Kazmierczak, M. Hackel, D. Hoban, 2016, Antimicrobial Agents and Chemotherapy.

In Vitro Activity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens

M. Hackel, D. Sahm, L. Miller, 2016, Antimicrobial Agents and Chemotherapy.

Worldwide Prevalence of Macrolide Resistance Genotypes among Streptococcus pneumoniae from 2004 to 2008

M. Hackel, D. Hoban, C. Lascols, 2009 .

Comparative Analysis of the Antibacterial Activity of a Novel Peptide Deformylase Inhibitor, GSK1322322

M. Hackel, D. Hoban, S. Bouchillon, 2013, Antimicrobial Agents and Chemotherapy.

Serotype prevalence and antibiotic resistance in Streptococcus pneumoniae clinical isolates among global populations.

M. Hackel, C. Lascols, S. Bouchillon, 2013, Vaccine.

In vitro susceptibility and distribution of beta-lactamases in Enterobacteriaceae causing intra-abdominal infections in North America 2010-2011.

K. Kazmierczak, M. Hackel, D. Hoban, 2014, Diagnostic microbiology and infectious disease.

Antimicrobial activity of ceftazidime-avibactam and comparators against levofloxacin-resistant Escherichia coli collected from four geographic regions, 2012–2018

M. Hackel, G. Stone, 2021, Annals of clinical microbiology and antimicrobials.

Potent LpxC Inhibitors with In Vitro Activity against Multidrug-Resistant Pseudomonas aeruginosa

F. Cohen, A. Jubb, M. Hackel, 2019, Antimicrobial Agents and Chemotherapy.

In vitro activity of the siderophore monosulfactam BAL30072 against meropenem-non-susceptible Acinetobacter baumannii.

M. Page, P. Higgins, M. Hackel, 2012, The Journal of antimicrobial chemotherapy.

Characterization of extended-spectrum beta-lactamases and antimicrobial resistance of Klebsiella pneumoniae in intra-abdominal infection isolates in Latin America, 2008-2012. Results of the Study for Monitoring Antimicrobial Resistance Trends.

K. Kazmierczak, M. Hackel, D. Hoban, 2015, Diagnostic microbiology and infectious disease.

Using Nucleic Acid Microarrays To Perform Molecular Epidemiology and Detect Novel (cid:1) -Lactamases: a Snapshot of Extended-Spectrum (cid:1) -Lactamases throughout the World

A. Hujer, M. Hackel, D. Hoban, 2012 .

Ceftibuten-Ledaborbactam Activity against Multidrug-Resistant and Extended-Spectrum-β-Lactamase-Positive Clinical Isolates of Enterobacterales from a 2018–2020 Global Surveillance Collection

M. Hackel, J. Karlowsky, D. Sahm, 2022, Antimicrobial agents and chemotherapy.

In Vitro Activity of Sulbactam-Durlobactam against Global Isolates of Acinetobacter baumannii-calcoaceticus Complex Collected from 2016 to 2021

S. McLeod, M. Hackel, J. Karlowsky, 2022, Antimicrobial agents and chemotherapy.

1 AAC 01304-21 R 1 1 2 In Vitro Activity of Ceftibuten / VNRX-5236 against Urinary Tract Infection Isolates of 3 Antimicrobial-Resistant Enterobacterales 4 5

M. Hackel, J. Karlowsky, D. Sahm, 2021 .

Trends in Susceptibility of Escherichia coli from Intra-Abdominal Infections to Ertapenem and Comparators in the United States According to Data from the SMART Program, 2009 to 2013

K. Kazmierczak, M. Hackel, D. Sahm, 2015, Antimicrobial Agents and Chemotherapy.

Dissemination of NDM Metallo-β-Lactamase Genes among Clinical Isolates of Enterobacteriaceae Collected during the SMART Global Surveillance Study from 2008 to 2012

K. Kazmierczak, M. Hackel, D. Hoban, 2014, Antimicrobial Agents and Chemotherapy.

Susceptibility of gram-negative aerobic bacilli from intra-abdominal pathogens to antimicrobial agents collected in the United States during 2011.

M. Hackel, D. Hoban, D. Goff, 2014, The Journal of infection.

Susceptibility of European Escherichia coli clinical isolates from intra-abdominal infections, extended-spectrum β-lactamase occurrence, resistance distribution, and molecular characterization of ertapenem-resistant isolates (SMART 2008-2009).

M. Hackel, R. Cantón, D. Hoban, 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

The in Vitro Activity of Tigecycline and Antimicrobial Cross-Resistance Against Enterobacteriaceae Worldwide

M. Hackel, D. Hoban, S. Bouchillon, 2008 .

Bacterial Resistance Patterns of Isolates from Various Body Sites: The European T.E.S.T. Program

M. Hackel, D. Hoban, J. Johnson, 2008 .

Tigecycline and Comparators Against Extended Spectrum Beta-Lactamase (ESBL) Isolates Worldwide

John L. Johnson, M. Hackel, D. Hoban, 2008 .

Evaluation of Tigecycline in the United States Against Antimicrobial Resistant Acinetobacter

M. Hackel, D. Hoban, J. Johnson, 2008 .

An Asia/Pacific Rim Perspective of Enterobacteriaceae Multi-drug Resistant (MDR) Isolates Against Tigecycline

John L. Johnson, M. Hackel, D. Hoban, 2008 .

An Evaluation of Tigecycline and Comparators in Asia/Pacific Rim for Often Difficult to Treat Pathogens

John L. Johnson, M. Hackel, D. Hoban, 2008 .

Evaluation of Tigecycline and Other Antimicrobials in Latin America Against Multi-drug Resistant (MDR) Staphylococcus aureus

John L. Johnson, M. Hackel, D. Hoban, 2008 .

P2051 Antibacterial activity of tigecycline against H. influenzae and S. pneumoniae (2004–06) Global Population –T.E.S.T. Program, 2006

John L. Johnson, M. Hackel, D. Hoban, 2007 .

P1684 Tigecycline in vitro activity against often difficult to treat European pathogens

John L. Johnson, M. Hackel, D. Hoban, 2007 .

P2048 Comparison of in vitro activity of tigecycline against pathogens from intensive care patients in Europe –T.E.S.T. Program 2006

John L. Johnson, M. Hackel, D. Hoban, 2007 .

P1121 Patterns of susceptibility of Gram-negatives/positives isolated in the United Kingdom and Ireland

John L. Johnson, M. Hackel, D. Hoban, 2007 .

Comparative Analysis of Tigecycline in South America from 2004-2007

John L. Johnson, M. Hackel, D. Hoban, 2007 .

In Vitro Activity of Tigecycline and 13 Comparators against Pathogens from a Global Population of Intensive Care Patients in 2007

John L. Johnson, M. Hackel, D. Hoban, 2007 .

#P 811 Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program - Global In Vitro Antibacterial Activity against Selected Species of Glucose Non-fermenting Organisms

John L. Johnson, M. Hackel, A. Hsiung, 2004 .

#P 441 Tigecycline Evaluation Surveillance Trial (T.E.S.T.) - In Vitro Antibacterial Activity against 9,063 Gram-positive and Gram-negative pathogens in the United States

John L. Johnson, M. Hackel, A. Hsiung, 2004 .

P 802 Global In Vitro Antibacterial Activity of Tigecycline against Methicillin Resistant and Methicillin Sensitive Staphylococcus aureus Isolates from the Tigecycline Evaluation Surveillance Trial (T.E.S.T.) Program

John L. Johnson, M. Hackel, A. Hsiung, 2004 .

Susceptibility of Staphylococcus aureus to topical agents in the United States: a sentinel study.

M. Hackel, D. Hoban, S. Bouchillon, 2014, Clinical therapeutics.

Global Dissemination of blaKPC into Bacterial Species beyond Klebsiella pneumoniae and In Vitro Susceptibility to Ceftazidime-Avibactam and Aztreonam-Avibactam

K. Kazmierczak, M. Hackel, P. Bradford, 2016, Antimicrobial Agents and Chemotherapy.

Evaluation of the Clinical and Laboratory Standards Institute phenotypic confirmatory test to detect the presence of extended-spectrum β-lactamases from 4005 Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae and Proteus mirabilis isolates.

I. Morrissey, M. Hackel, D. Hoban, 2014, Journal of medical microbiology.

In Vitro Potency of Tigecycline Against Pathogens from Most Common Body Sites: A Study in Asia/Pacific Rim

M. Hackel, D. Hoban, J. Johnson, 2008 .

Tigecycline Comparison with Minocycline Resistance Pathogens. A Worldwide Perspective

John L. Johnson, M. Hackel, D. Hoban, 2008 .

A Global Evaluation of Vancomycin Resistant Enterococci (VRE) Against Tigecycline: The T.E.S.T. Program

John L. Johnson, M. Hackel, D. Hoban, 2008 .

Evaluation of Multidrug Resistant (MDR) Isolates Against Tigecycline: A Canadian Perspective

M. Hackel, D. Hoban, J. Johnson, 2008 .

Evaluation of 11 Antimicrobial Agents Against Australian Bacteremia Isolates: The T.E.S.T. Program

M. Hackel, D. Hoban, J. Johnson, 2008 .

Tigecycline and Comparators Against S. pneumoniae: A Global Study

M. Hackel, D. Hoban, J. Johnson, 2008 .

P1685 In vitro activity of tigecycline and 10 common therapeutic agents against methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus species – Global Data, 2004 – 2006

John L. Johnson, M. Hackel, D. Hoban, 2007 .

Molecular epidemiology of Enterobacteriaceae that produce VIMs and IMPs from the SMART surveillance program.

G. Peirano, M. Hackel, J. Pitout, 2014, Diagnostic microbiology and infectious disease.

Prevalence of RND efflux pump regulator variants associated with tigecycline resistance in carbapenem-resistant Acinetobacter baumannii from a worldwide survey.

P. Higgins, M. Hackel, H. Seifert, 2021, The Journal of antimicrobial chemotherapy.

Etiology, Extended-spectrum &bgr;-lactamase Rates and Antimicrobial Susceptibility of Gram-negative Bacilli Causing Intra-abdominal Infections in Patients in General Pediatric and Pediatric Intensive Care Units—Global Data From The Study for Monitoring Antimicrobial Resistance Trends 2008 to 2010

M. Hackel, D. Hoban, S. Hawser, 2013, The Pediatric infectious disease journal.

Trends in susceptibility of selected gram-negative bacilli isolated from intra-abdominal infections in North America: SMART 2005-2010.

M. Hackel, D. Hoban, S. Hawser, 2013, Diagnostic microbiology and infectious disease.

Using Nucleic Acid Microarrays To Perform Molecular Epidemiology and Detect Novel β-Lactamases: a Snapshot of Extended-Spectrum β-Lactamases throughout the World

R. Bonomo, A. Hujer, M. Hackel, 2012, Journal of Clinical Microbiology.

In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).

K. Kazmierczak, M. Hackel, R. Echols, 2019, International journal of antimicrobial agents.

Epidemiology and Antimicrobial Susceptibility of Gram-Negative Pathogens Causing Intra-abdominal Infections in Pediatric Patients in Europe—SMART 2011–2014

M. Hackel, D. Sahm, R. Badal, 2016, Journal of the Pediatric Infectious Diseases Society.

Diagnostic Microbiology and Infectious Disease

K. Kazmierczak, M. Hackel, D. Hoban, 2014 .

M. Hackel, E. Kim, S. Hawser, 2012, International journal of antimicrobial agents.

Activity of Ertapenem against Enterobacteriaceae in seven global regions—SMART 2012–2016

M. Hackel, M. Motyl, D. Hoban, 2018, European Journal of Clinical Microbiology & Infectious Diseases.

Activity of Ertapenem against Enterobacteriaceae in seven global regions—SMART 2012–2016

M. Hackel, M. Motyl, D. Hoban, 2018, European Journal of Clinical Microbiology & Infectious Diseases.

In Vitro Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program

D. Daigle, M. Hackel, J. Karlowsky, 2022, Antimicrobial agents and chemotherapy.

Susceptibility of Klebsiella pneumoniae Isolates from Intra-Abdominal Infections and Molecular Characterization of Ertapenem-Resistant Isolates

N. Woodford, D. Livermore, M. Hackel, 2011, Antimicrobial Agents and Chemotherapy.

Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from global surveillance program (SIDERO-WT-2014).

M. Hackel, D. Sahm, Naoki Kohira, 2020, Journal of global antimicrobial resistance.

Reproducibility of broth microdilution MICs for the novel siderophore cephalosporin, cefiderocol, determined using iron-depleted cation-adjusted Mueller-Hinton broth.

M. Hackel, J. Karlowsky, R. Echols, 2019, Diagnostic microbiology and infectious disease.

In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015.

M. Hackel, J. Karlowsky, R. Echols, 2019, International journal of antimicrobial agents.

Epidemiology and Detect Novel β-Lactamases: a Snapshot of ESBLs

R. Bonomo, A. Hujer, M. Hackel, 2012 .

Surveillance and Molecular Epidemiology of Klebsiella pneumoniae Isolates That Produce Carbapenemases: First Report of OXA-48-Like Enzymes in North America

G. Peirano, K. Laupland, M. Hackel, 2012, Antimicrobial Agents and Chemotherapy.

In Vitro activities of Tedizolid and comparator antimicrobial agents against clinical isolates of Staphylococcus aureus collected in 12 countries from 2014 to 2016.

M. Hackel, J. Karlowsky, D. Sahm, 2017, Diagnostic microbiology and infectious disease.

In vitro activity of tigecycline against carbapenemase-producing Acinetobacter baumannii.

P. Higgins, M. Hackel, H. Seifert, 2010, International journal of antimicrobial agents.

In vitro activity of tigecycline against molecularly characterised strains of Enterobacteriaceae isolated from phase 3 clinical trials and the Tigecycline Evaluation and Surveillance Trial (TEST).

M. Hackel, M. Wible, S. Bouchillon, 2015, Journal of Global Antimicrobial Resistance.

In Vitro Activity of Ceftaroline against Bacterial Pathogens Isolated from Patients with Skin and Soft Tissue and Respiratory Tract Infections in the Middle East and Africa: AWARE Global Surveillance Program 2015-2018.

M. Hackel, J. Karlowsky, D. Sahm, 2020, Journal of global antimicrobial resistance.

In vitro activity of Ceftaroline against bacterial pathogens isolated from patients with skin and soft tissue and respiratory tract infections in African and Middle Eastern countries: AWARE global surveillance program 2012-2014.

M. Hackel, J. Karlowsky, D. Sahm, 2016, Diagnostic microbiology and infectious disease.

Multicenter Performance Assessment of Carba NP Test

Robin Patel, J. Mandrekar, R. Humphries, 2017, Journal of Clinical Microbiology.

In vitro activity of sulbactam/durlobactam against clinical isolates of Acinetobacter baumannii collected in China.

M. Hackel, P. Bradford, Qiwen Yang, 2020, The Journal of antimicrobial chemotherapy.

In Vitro Activity of Sulbactam-Durlobactam against Acinetobacter baumannii-calcoaceticus Complex Isolates Collected Globally in 2016 and 2017

S. McLeod, M. Hackel, Alita A. Miller, 2020, Antimicrobial Agents and Chemotherapy.

Global Surveillance of the Activity of Sulbactam Combined With the Novel β-lactamase Inhibitor ETX2514 Against Clinical Isolates of Acinetobacter baumannii From 2014

M. Hackel, R. Tommasi, B. Dejonge, 2016 .

Antimicrobial susceptibility of Gram‐negative ESKAPE pathogens isolated from hospitalized patients with intra‐abdominal and urinary tract infections in Asia‐Pacific countries: SMART 2013‐2015

M. Hackel, J. Karlowsky, D. Hoban, 2017, Journal of medical microbiology.

Correlation of β-Lactamase Production and Colistin Resistance among Enterobacteriaceae Isolates from a Global Surveillance Program

K. Kazmierczak, M. Hackel, P. Bradford, 2015, Antimicrobial Agents and Chemotherapy.

1273. Activity of Ceftolozane/Tazobactam and Comparators Against Enterobacterales and P. aeruginosa Isolates from Pediatric Patients—SMART United States 2017-2019

M. Hackel, M. Motyl, D. Sahm, 2021, Open Forum Infectious Diseases.

Invitro activity of imipenem-relebactam against gram-negative bacilli isolated from patients with lower respiratory tract infections in the United States in 2015 - Results from the SMART global surveillance program.

K. Kazmierczak, M. Hackel, M. Motyl, 2017, Diagnostic microbiology and infectious disease.

Changes in the antibiotic susceptibility of anaerobic bacteria from 2007-2009 to 2010-2012 based on the CLSI methodology.

Maria Karlsson, Audrey N Schuetz, L. Koeth, 2016, Anaerobe.

Epidemiology and antimicrobial susceptibility of Gram-negative aerobic bacteria causing intra-abdominal infections during 2010–2011

I. Morrissey, M. Hackel, D. Hoban, 2015, Journal of chemotherapy.

In Vitro Activity of AZD0914, a Novel Bacterial DNA Gyrase/Topoisomerase IV Inhibitor, against Clinically Relevant Gram-Positive and Fastidious Gram-Negative Pathogens

M. Huband, M. Hackel, P. Bradford, 2015, Antimicrobial Agents and Chemotherapy.

Collective assessment of antimicrobial susceptibility among the most common Gram-negative respiratory pathogens driving therapy in the ICU

M. Hackel, M. Motyl, P. Moise, 2021, JAC-antimicrobial resistance.

Resistance Rates of Intra-Abdominal Isolates from Intensive Care Units and Non-Intensive Care Units in the United States: The Study for Monitoring Antimicrobial Resistance Trends 2010-2012.

M. Hackel, D. Hoban, S. Bouchillon, 2015, Surgical infections.

Erratum for Karlowsky et al., “In Vitro Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies, 2014 to 2019”

M. Hackel, J. Karlowsky, R. Echols, 2023, Antimicrobial Agents and Chemotherapy.

Molecular Characterization of Methicillin-Susceptible Staphylococcus aureus Clinical Isolates in the United States, 2004 to 2010

F. Lowy, M. Hackel, A. Uhlemann, 2013, Journal of Clinical Microbiology.

Relebactam restores susceptibility of resistant Pseudomonas aeruginosa and Enterobacterales and enhances imipenem activity against chromosomal AmpC-producing species: analysis of global SMART 2018–2020

D. Hilbert, M. Hackel, M. Motyl, 2023, BMC Microbiology.

In Vitro Activity of Ceftibuten-Avibactam against β-Lactamase-Positive Enterobacterales from the ATLAS Global Surveillance Program

M. Hackel, J. Karlowsky, D. Sahm, 2023, Antimicrobial agents and chemotherapy.

Epidemiology and susceptibility of Gram-negative appendicitis pathogens: SMART 2008-2010.

M. Hackel, D. Hoban, S. Hawser, 2013, Surgical infections.

Diagnostic Microbiology and Infectious Disease

K. Kazmierczak, M. Hackel, D. Hoban, 2014 .

Comparative Analysis of the Antibacterial Activity of a Novel Peptide Deformylase Inhibitor, GSK1322322

M. Hackel, D. Hoban, S. Bouchillon, 2013, Antimicrobial Agents and Chemotherapy.

Surveillance and Molecular Epidemiology of Klebsiella pneumoniae Isolates That Produce Carbapenemases: First Report of OXA-48-Like Enzymes in North America

G. Peirano, K. Laupland, M. Hackel, 2012, Antimicrobial Agents and Chemotherapy.

Global Incidence of Carbapenemase-Producing Escherichia coli ST131

G. Peirano, K. Kazmierczak, M. Hackel, 2014, Emerging infectious diseases.

Epidemiology and susceptibility of Gram-negative appendicitis pathogens: SMART 2008-2010.

M. Hackel, D. Hoban, S. Hawser, 2013, Surgical infections.